1. Home
  2. TNDM vs ABCL Comparison

TNDM vs ABCL Comparison

Compare TNDM & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNDM
  • ABCL
  • Stock Information
  • Founded
  • TNDM 2006
  • ABCL 2012
  • Country
  • TNDM United States
  • ABCL Canada
  • Employees
  • TNDM N/A
  • ABCL N/A
  • Industry
  • TNDM Medical/Dental Instruments
  • ABCL Biotechnology: Pharmaceutical Preparations
  • Sector
  • TNDM Health Care
  • ABCL Health Care
  • Exchange
  • TNDM Nasdaq
  • ABCL Nasdaq
  • Market Cap
  • TNDM 1.1B
  • ABCL 1.1B
  • IPO Year
  • TNDM 2013
  • ABCL 2020
  • Fundamental
  • Price
  • TNDM $11.93
  • ABCL $4.39
  • Analyst Decision
  • TNDM Buy
  • ABCL Strong Buy
  • Analyst Count
  • TNDM 15
  • ABCL 5
  • Target Price
  • TNDM $23.60
  • ABCL $8.00
  • AVG Volume (30 Days)
  • TNDM 2.7M
  • ABCL 5.5M
  • Earning Date
  • TNDM 08-06-2025
  • ABCL 08-07-2025
  • Dividend Yield
  • TNDM N/A
  • ABCL N/A
  • EPS Growth
  • TNDM N/A
  • ABCL N/A
  • EPS
  • TNDM N/A
  • ABCL N/A
  • Revenue
  • TNDM $1,001,719,000.00
  • ABCL $32,875,999.00
  • Revenue This Year
  • TNDM $8.91
  • ABCL N/A
  • Revenue Next Year
  • TNDM $10.94
  • ABCL $71.11
  • P/E Ratio
  • TNDM N/A
  • ABCL N/A
  • Revenue Growth
  • TNDM 25.84
  • ABCL N/A
  • 52 Week Low
  • TNDM $9.98
  • ABCL $1.89
  • 52 Week High
  • TNDM $47.60
  • ABCL $5.82
  • Technical
  • Relative Strength Index (RSI)
  • TNDM 40.35
  • ABCL 51.44
  • Support Level
  • TNDM $10.25
  • ABCL $4.01
  • Resistance Level
  • TNDM $11.30
  • ABCL $4.81
  • Average True Range (ATR)
  • TNDM 0.86
  • ABCL 0.36
  • MACD
  • TNDM 0.08
  • ABCL -0.05
  • Stochastic Oscillator
  • TNDM 35.07
  • ABCL 42.59

About TNDM Tandem Diabetes Care Inc.

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Share on Social Networks: